A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma.
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Bifikafusp alfa (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Philogen
- 13 Apr 2022 Planned End Date changed from 1 Jun 2017 to 1 Jun 2022.
- 28 Jul 2018 The study has been discontinued in Germany
- 27 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.